Attenua is a clinical-stage biotechnology company developing novel medicines for the millions of patients who suffer from chronic respiratory disorders such as chronic cough. Cough is a medical problem for which no new drugs (NMEs/NCEs) have been approved in the U.S. since 1958. There is no approved medication for treating chronic cough.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/30/18 | $35,000,000 | Series A |
Abingworth Omega Funds  OrbiMed Advisors Redmile Group | undisclosed |
